Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06905301
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Ribociclib — DRUG
    CDK4/6 inhibitor
  • Letrozole — DRUG
    Aromatase inhibitor
  • Anastrozole — DRUG
    Aromatase inhibitor

Study Details

This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.

Key Dates

Start date
Jan 23, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
240 participants (estimated)

Arms

  • Arm: Using Application
    HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that use the web application
  • Arm: Non using Application
    HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that do not use the web application

Primary Outcome Measure

Number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period [ Time Frame: 12 months ]

Central Contacts

Related Studies